pCMV-T7-ABE8.20m-nSpG-P2A-EGFP (KAC1160)
(Plasmid
#185916)
-
PurposepCMV and pT7 plasmid encoding human codon optimized ABE8.20m A-to-G base editor with nickase SpG(D10A/D1135L/S1136W/G1218K/E1219Q/R1335Q/T1337R) and P2A-EGFP
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 185916 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepCMV_ABEmax_P2A_GFP
-
Backbone manufacturerAddgene Plasmid #112101
-
Vector typeMammalian Expression ; in vitro transcription; T7 promoter
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namehuman codon optimized ABE8.20m-nSpG-P2A-EGFP
-
Alt nameKAC1160
-
SpeciesSynthetic
-
MutationnSpG=D10A/D1135L/S1136W/G1218K/E1219Q/R1335Q/T1337R
- Promoter CMV and T7
-
Tags
/ Fusion Proteins
- BPNLS (N terminal on insert)
- BPNLS-3xFLAG-P2A-EGFP (C terminal on insert)
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer oBK6928-CCAAGTCTCCACCCCATTGACG
- 3′ sequencing primer oBK219-GGGAGTGGCACCTTCCAGGGTC (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Please visit https://www.biorxiv.org/content/10.1101/2023.01.20.524978v1 for bioRxiv preprint.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pCMV-T7-ABE8.20m-nSpG-P2A-EGFP (KAC1160) was a gift from Benjamin Kleinstiver (Addgene plasmid # 185916 ; http://n2t.net/addgene:185916 ; RRID:Addgene_185916) -
For your References section:
Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy. Alves CRR, Ha LL, Yaworski R, Sutton ER, Lazzarotto CR, Christie KA, Reilly A, Beauvais A, Doll RM, de la Cruz D, Maguire CA, Swoboda KJ, Tsai SQ, Kothary R, Kleinstiver BP. Nat Biomed Eng. 2023 Dec 6. doi: 10.1038/s41551-023-01132-z. 10.1038/s41551-023-01132-z PubMed 38057426